Letrozol Accord

Letrozole, the active ingredient in Letrozol Accord, is a aromatase inhibitor presented as an oral tablet for oral use. It is employed in the treatment of hormone receptor‑positive breast cancer in postmenopausal women.

GNH USA supplies Letrozol Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Letrozole acts on the estrogen‑dependent breast cancer pathway and is indicated for several stages of the disease. - Adjuvant treatment of hormone receptor‑positive breast cancer: reduces risk of recurrence after surgery. - Metastatic hormone receptor‑positive breast cancer: slows disease progression in advanced cases. - Neoadjuvant therapy for breast cancer: shrinks tumors before definitive surgery.

Letrozole may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Hot flashes: transient episodes of intense warmth. - Joint pain: aching or stiffness in joints. - Fatigue: persistent tiredness. - Nausea: mild upset stomach. - Headache: occasional throbbing pain. - Increased cholesterol: elevation of blood lipid levels.

Serious or Rare Side Effects: - Osteoporosis: decreased bone mineral density leading to fractures. - Deep vein thrombosis: formation of blood clots in veins. - Liver dysfunction: abnormal liver enzyme elevations. - Severe allergic reaction: rash, swelling, or breathing difficulty. - Cardiovascular events: increased risk of heart disease. - Vision changes: blurred or altered vision.

Before initiating Letrozole therapy, consider the following safety measures. - Bone health assessment: evaluate risk of osteoporosis and consider calcium/vitamin D supplementation. - Cardiovascular monitoring: check blood pressure and lipid profile regularly. - Liver function tests: perform baseline and periodic liver enzyme assessments. - Drug interactions: review concomitant medications for potential interactions. - Pregnancy contraindication: avoid use in pregnant or nursing women; effective contraception required. - Store below 25°C: keep in the original pack, protect from moisture.

Letrozole can interact with several medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce Letrozole plasma levels. - Tamoxifen: antagonistic effect on estrogen suppression.

Moderate Interactions (Monitor Closely): - CYP2A6 inhibitors (e.g., fluvoxamine): may increase Letrozole exposure. - Anticoagulants (e.g., warfarin): may enhance bleeding risk. - Cholesterol‑lowering agents (e.g., statins): monitor lipid changes. - Hormone replacement therapy: may diminish therapeutic effect. - SSRIs/SNRIs: potential additive effects on mood or fatigue.